Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Deferred Revenue (2020 - 2024)

Historic Current Deferred Revenue for Janux Therapeutics (JANX) over the last 5 years, with Q2 2024 value amounting to $94000.0.

  • Janux Therapeutics' Current Deferred Revenue fell 9823.97% to $94000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $94000.0, marking a year-over-year decrease of 9823.97%. This contributed to the annual value of $1.7 million for FY2023, which is 6846.1% down from last year.
  • Janux Therapeutics' Current Deferred Revenue amounted to $94000.0 in Q2 2024, which was down 9823.97% from $972000.0 recorded in Q1 2024.
  • Over the past 5 years, Janux Therapeutics' Current Deferred Revenue peaked at $8.0 million during Q4 2020, and registered a low of $94000.0 during Q2 2024.
  • Its 5-year average for Current Deferred Revenue is $4.4 million, with a median of $5.1 million in 2021.
  • As far as peak fluctuations go, Janux Therapeutics' Current Deferred Revenue surged by 1219.6% in 2022, and later tumbled by 9823.97% in 2024.
  • Quarter analysis of 5 years shows Janux Therapeutics' Current Deferred Revenue stood at $8.0 million in 2020, then plummeted by 35.46% to $5.2 million in 2021, then increased by 4.71% to $5.4 million in 2022, then tumbled by 68.46% to $1.7 million in 2023, then crashed by 94.49% to $94000.0 in 2024.
  • Its Current Deferred Revenue stands at $94000.0 for Q2 2024, versus $972000.0 for Q1 2024 and $1.7 million for Q4 2023.